Optimal Screening Cut-Off ID'd for GDM in Twin Pregnancies

This article originally appeared here.
Share this content:
Optimal Screening Cut-Off ID'd for GDM in Twin Pregnancies
Optimal Screening Cut-Off ID'd for GDM in Twin Pregnancies

(HealthDay News) -- The optimal one-hour 50-g glucose challenge test (GCT) screening cut-off for gestational diabetes mellitus (GDM) is ≥135 mg/dL in twin pregnancies, according to a study published online Oct. 14 in the American Journal of Obstetrics & Gynecology.

Andrei Rebarber, M.D., from the Icahn School of Medicine at Mount Sinai in New York City, and colleagues examined the ideal GCT cut-off in twin pregnancies undergoing GDM screening from a historical cohort of patients. Four hundred seventy-five patients underwent a one-hour 50-g GCT at 24 to 28 weeks of gestation, and those with a GCT of ≥130 mg/dL underwent a three-hour 100-g oral glucose tolerance test. The testing characteristics of the GCT for GDM diagnosis were assessed at cut-offs of ≥130 mg/dL, ≥135 mg/dL, and ≥140 mg/dL.

The researchers found that the incidence of GDM was 6.5 percent. The positive screen rates were: ≥130 mg/dL, 34.7 percent; ≥135 mg/dL, 28.6 percent; and ≥140, 23.4 percent. With a cut-off of ≥135 mg/dL, sensitivity and specificity were 100 and 76.4 percent, respectively. The positive and negative predictive values were 22.8 and 100 percent, respectively, at this cut-off. A cut-off of ≥135 mg/dL versus ≥130 mg/dL resulted in 6.1 percent fewer patients testing positive, without affecting sensitivity.

"In twin pregnancies, the optimal one-hour 50-g GCT screening cut-off appears to be ≥135 mg/dL," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »